Literature DB >> 16226335

Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia.

Ruth De Bruyne1, Bernard Portmann, Marianne Samyn, Sanjay Bansal, Alex Knisely, Giorgina Mieli-Vergani, Anil Dhawan.   

Abstract

BACKGROUND/AIMS: The United Kingdom (UK) acute lymphoblastic leukaemia (ALL) 97/99 clinical trial compared 6-mercaptopurine (6MP) with 6-thioguanine (6TG) as maintenance therapy for childhood ALL. Review of interim results has led to discontinuation of the 6TG arm.
METHODS: We report six children with ALL, who presented with splenomegaly after a median (range) treatment duration of 12 (6-22) months. All these children were treated in the 6TG-arm.
RESULTS: The median (range) age at presentation was 6.6 (3.2-11.5) years. There were five boys. The presenting features were splenomegaly in all and hepatomegaly in four. AST was abnormal in one (80 IU/l, normal range 10-50). Abdominal sonography showed an altered texture of the liver parenchyma and confirmed splenomegaly. Microscopy showed findings within the spectrum of occlusive venopathy and nodular regenerative hyperplasia (NRH). After a median (range) follow-up of 23 (4-36) months splenomegaly and thrombocytopenia, suggestive of progressive portal hypertension, continue to worsen in all children.
CONCLUSIONS: 6TG is associated with chronic hepatic toxicity and progressive portal hypertension on follow-up. Microscopy showed NRH in all patients with features in keeping with an intrahepatic occlusive venopathy and variable parenchymal atrophy and loss.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226335     DOI: 10.1016/j.jhep.2005.06.020

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

1.  The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV.

Authors:  Thomas D Schiano; Alison Uriel; Douglas T Dieterich; M Isabel Fiel
Journal:  Virchows Arch       Date:  2010-11-06       Impact factor: 4.064

Review 2.  Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature.

Authors:  T N Witte; A L Ginsberg
Journal:  Can J Gastroenterol       Date:  2008-02       Impact factor: 3.522

Review 3.  Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children's Oncology Group.

Authors:  Sharon Castellino; Andrew Muir; Ami Shah; Sheila Shope; Kevin McMullen; Kathy Ruble; Ashley Barber; Andrew Davidoff; Melissa M Hudson
Journal:  Pediatr Blood Cancer       Date:  2010-05       Impact factor: 3.167

4.  A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.

Authors:  Alexander Teml; Matthias Schwab; Daan W Hommes; Sven Almer; Milan Lukas; Thomas Feichtenschlager; Timothy Florin; Julia Seiderer; Wolfgang Petritsch; Bernd Bokemeyer; Wolfgang Kreisel; Klaus R Herrlinger; Peter Knoflach; Bruno Bonaz; Thomas Klugmann; Hans Herfarth; Nikolaus Pedarnig; Walter Reinisch
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 5.  Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.

Authors:  Eric J Chow; Lynnette Anderson; K Scott Baker; Smita Bhatia; Gregory M T Guilcher; Jennifer T Huang; Wendy Pelletier; Joanna L Perkins; Linda S Rivard; Tal Schechter; Ami J Shah; Karla D Wilson; Kenneth Wong; Satkiran S Grewal; Saro H Armenian; Lillian R Meacham; Daniel A Mulrooney; Sharon M Castellino
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-21       Impact factor: 5.742

Review 6.  Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.

Authors:  My-Linh Tran-Minh; Paula Sousa; Marianne Maillet; Matthieu Allez; Jean-Marc Gornet
Journal:  World J Hepatol       Date:  2017-05-08

7.  Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.

Authors:  Ahmed B Bayoumy; Elsa L S A van Liere; Melek Simsek; Ben Warner; Aathavan Loganayagam; Jeremy D Sanderson; Simon Anderson; Jonathan Nolan; Nanne K de Boer; Chris J J Mulder; Azhar Ansari
Journal:  BMC Gastroenterol       Date:  2020-09-11       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.